Last reviewed · How we verify
Fe-ASP — Competitive Intelligence Brief
marketed
Asparaginase conjugate
Asparagine synthetase (indirect target via asparagine depletion)
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Fe-ASP (Fe-ASP) — Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.. Fe-ASP is an iron-asparaginase conjugate that depletes asparagine while delivering iron supplementation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fe-ASP TARGET | Fe-ASP | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | marketed | Asparaginase conjugate | Asparagine synthetase (indirect target via asparagine depletion) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Asparaginase conjugate class)
- Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fe-ASP CI watch — RSS
- Fe-ASP CI watch — Atom
- Fe-ASP CI watch — JSON
- Fe-ASP alone — RSS
- Whole Asparaginase conjugate class — RSS
Cite this brief
Drug Landscape (2026). Fe-ASP — Competitive Intelligence Brief. https://druglandscape.com/ci/fe-asp. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab